Roche Holding AG
ROG
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
112,774
Roche Holding AG News & Analysis
personal-finance
The US dollar looks overvalued. Should individual investors care?
Some things are a lot more important to professional investors than everybody else.
stocks
3 cheap Wide Moat stocks in a divided industry
All but a couple of shares in this industry have sold off. Our analysts think these three high quality companies have fallen too far.
stocks
Obesity drug stocks: Where to invest now
Eli Lilly and Novo Nordisk have staged big rallies. Here’s how investors can approach this potentially huge opportunity.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,976.80 | 20.70 | 0.23% |
| CAC 40 | 7,968.20 | 25.29 | -0.32% |
| DAX 40 | 23,576.94 | 391.69 | -1.63% |
| Dow JONES (US) | 47,706.51 | 34.29 | -0.07% |
| FTSE 100 | 10,311.94 | 100.30 | -0.96% |
| HKSE | 25,898.76 | 61.14 | -0.24% |
| NASDAQ | 22,697.10 | 1.16 | 0.01% |
| Nikkei 225 | 55,025.37 | 776.98 | 1.43% |
| NZX 50 Index | 13,293.13 | 198.76 | 1.52% |
| S&P 500 | 6,781.48 | 14.51 | -0.21% |
| S&P/ASX 200 | 8,743.50 | 19.40 | 0.22% |
| SSE Composite Index | 4,133.43 | 10.29 | 0.25% |